Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials

被引:12
|
作者
Canafax, Daniel M. [2 ]
Bhanegaonkar, Abhijeet [3 ]
Bharmal, Murtuza [4 ]
Calloway, Michael [1 ]
机构
[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
[2] XenoPort Inc, Santa Clara, CA USA
[3] W Virginia Univ, Sch Pharm, Morgantown, WV 26506 USA
[4] Quintiles, Rockville, MD USA
关键词
QUALITY-OF-LIFE; MEDICAL OUTCOMES; SYNDROME RLS; EPIDEMIOLOGY; DIAGNOSIS; DISEASE; SCALE;
D O I
10.1186/1471-2377-11-48
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials investigating RLS treatments. The objective of this study was to validate a new measure, the Post Sleep Questionnaire (PSQ), to assess sleep dysfunction in subjects with moderate-to-severe RLS symptoms. Methods: Pooled data were analyzed from two 12-week, randomized, placebo-controlled trials of gabapentin enacarbil (N = 540). At baseline and Week 12, subjects completed the PSQ and other validated health surveys: IRLS Rating Scale, Clinical Global Impression of Improvement (CGI-I), Profile of Mood States (POMS), Medical Outcomes Study Scale-Sleep (MOS-Sleep), and RLS-Quality of Life (RLSQoL). Pooled data were used post hoc to examine the convergent, divergent, known-group validity and the responsiveness of the PSQ. Results: Convergent validity was demonstrated by significant correlations between baseline PSQ items and total scores of IRLS, POMS, RLSQoL, and the MOS-Sleep Scale (p = 0.007 each). Divergent validity was demonstrated through the lack of significant correlations between PSQ items and demographic characteristics. Correlations (p < 0.0001) between RLS severity groups and PSQ items demonstrated known-group validity. Mean changes in investigator-and subject-rated CGI-I scores for each PSQ item (p < 0.0001) demonstrated the PSQ's responsiveness to patient change as reported by their care provider. Conclusions: Although these analyses were potentially limited by the use of clinical trial data and not prospective data from a study conducted solely for validation purposes, the PSQ demonstrated robust psychometric properties and is a valid instrument for assessing sleep and sleep improvements in subjects with moderate-to-severe RLS symptoms.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome
    Sloand, JA
    Shelly, MA
    Feigin, A
    Bernstein, P
    Monk, RD
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : 663 - 670
  • [32] Pergolide treatment of the Restless Legs Syndrome: A double-blind placebo-controlled study with objective assessment of leg movements
    Allen, RP
    Earley, CJ
    Hening, WA
    Walters, AS
    Yaffee, J
    Wagner, ML
    NEUROLOGY, 1998, 50 (04) : A68 - A69
  • [33] Rotigotine Transdermal System in the Treatment of Idiopathic Restless Logs Syndrome: Combined Results from Two Double-Blind, Placebo-Controlled, Multicenter Studies in Europe and the US
    Trenkwalder, Claudia
    Allen, Richard
    Hening, Wayne
    Schollmayer, Erwin
    NEUROLOGY, 2009, 72 (11) : A339 - A339
  • [34] Predictors of clinical response in a double-blind placebo controlled crossover trial of gabapentin enacarbil for restless legs syndrome
    Winkelman, John W.
    Jaros, Mark J.
    SLEEP MEDICINE, 2018, 48 : 1 - 7
  • [35] Ropinirole versus placebo in the treatment of restless legs syndrome (RLS): A 12-week multicenter double-blind placebo-controlled study conducted in 6 countries
    Walters, AS
    Ondo, W
    Sethi, K
    Dreykluft, T
    Gruustein, R
    SLEEP, 2003, 26 : A344 - A344
  • [36] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RESPONSE STUDY TO ASSESS THE PHARMACOKINETICS AND TOLERABILITY OF GABAPENTIN ENACARBIL IN SUBJECTS WITH RESTLESS LEGS SYNDROME
    Lal, R.
    Zomorodi, K.
    Atluri, H.
    Luo, W.
    Tovera, J.
    Chen, D.
    Hurt, J.
    Bonzo, D.
    Lassauzet, M.
    Cundy, K. C.
    SLEEP, 2009, 32 : A303 - A303
  • [37] A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics and tolerability of gabapentin enacarbil in subjects with restless legs syndrome
    Cundy, K. C.
    Lal, R.
    Zomorodi, K.
    Atluri, H.
    Luo, W.
    Chen, D.
    Hurt, J.
    Bonzo, D.
    Lassauzet, M. -L.
    DeRossett, S. E.
    MOVEMENT DISORDERS, 2009, 24 : S438 - S439
  • [38] Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: Results from a multi-center, randomized, double-blind, placebo-controlled trial
    Ma, Jian-Fang
    Wan, Qi
    Hu, Xin-Yue
    Sun, Sheng-Gang
    Wang, Wei-Zhi
    Zhao, Zhong-Xin
    Wang, Yong-Jun
    Liu, Chun-Feng
    Li, Ji-Mei
    Jiang, Yu-Ping
    Chen, Sheng-Di
    SLEEP MEDICINE, 2012, 13 (01) : 58 - 63
  • [39] AN ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS ASSESSING THE EFFECT OF MILNACIPRAN FOR FIBROMYALGIA
    Geisser, M. E.
    Palmer, R. H.
    Wang, Y.
    Gendreau, R. M.
    Trifilo, M.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 19 - 19
  • [40] Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome:: a randomised, double-blind, placebo-controlled trial
    Trenkwalder, Claudia
    Benes, Heike
    Poewe, Werner
    Oertel, Wolfgang H.
    Garcia-Borreguero, Diego
    de Weerd, Al W.
    Ferini-Strambi, Luigi
    Montagna, Pasquale
    Odin, Per
    Stiasny-Kolster, Karin
    Hoegl, Birgit
    Chaudhuri, K. Ray
    Partinen, Markku
    Schollmayer, Erwin
    Kohnen, Ralf
    LANCET NEUROLOGY, 2008, 7 (07): : 595 - 604